Ferté, Charles

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Sun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 1,236

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 720

Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells

Sun, R., Sundahl, N., Hecht, M., Putz, F., Lancia, A., Rouyar, A., Milic, M., Carré, A., Battistella, E., Alvarez Andres, E., et al. (2020) · Journal for ImmunoTherapy of Cancer

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 94

Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium

Franzoi, M. A., Ferreira, A. R., Lemaire, A., Rodriguez, J., Grosjean, J., Ribeiro, J. M., Polastro, L., Grellety, T., Artignan, X., Le Du, K., et al. (2024) · The Lancet Regional Health - Europe

Telemedicine and Telehealth ImplementationCancer survivorship and care

Cited by 50